MedPath
HSA Approval

Amvuttra solution for injection in pre-filled syringe 25mg

SIN17124P

Amvuttra solution for injection in pre-filled syringe 25mg

Amvuttra solution for injection in pre-filled syringe 25mg

October 25, 2024

NYPRAX PHARMA PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantNYPRAX PHARMA PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, SOLUTION

SUBCUTANEOUS

Medical Information

N07XX18

Manufacturer Information

NYPRAX PHARMA PTE. LTD.

Vetter Pharma-Fertigung GmbH & Co. KG

Active Ingredients

Vutrisiran (as vutrisiran sodium)

25mg

Vutrisiran Sodium

Documents

Package Inserts

Amvuttra Solution for Injection in Pre-filled Syringe PI.pdf

Approved: October 25, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Amvuttra solution for injection in pre-filled syringe 25mg - HSA Approval | MedPath